Protocol Ledger

NCT07720271 · Phase III · RECRUITING

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Interventional Phase III clinical trial protocol NCT07720271 sponsored by Novo Nordisk in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-31 Enrollment: 950 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07720271
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)950 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07720271
Protocol FieldVerified Registry Value
NCT IdentifierNCT07720271
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment950 participants (ESTIMATED)
Registered Start Date2026-08-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07720271
Hospital Research SiteLocationSite Profile
Providence Medical FoundationFullerton, CAOpen Hospital Dossier ->
Diablo Clinical Research IncWalnut Creek, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI